Myriad Genetics (MYGN) Tops Q3 EPS by 4c, provides guidance
Tweet
Share
E-mail
Get Alerts MYGN Hot Sheet
Price: $4.50 --0%
EPS Growth %: -220.0%
Financial Fact:
Interest income: 300K
Today's EPS Names:
JFIN, KEQU, LASE, More
EPS Growth %: -220.0%
Financial Fact:
Interest income: 300K
Today's EPS Names:
JFIN, KEQU, LASE, More
Join SI Premium – FREE
Myriad Genetics (NASDAQ: MYGN) reported Q3 EPS of $0.06, $0.04 better than the analyst estimate of $0.02. Revenue for the quarter came in at $213.3 million versus the consensus estimate of $210.76 million.
GUIDANCE:
Myriad Genetics sees FY2024 EPS of $0.12-$0.14, versus the consensus of $0.10. Myriad Genetics sees FY2024 revenue of $837-843 million, versus the consensus of $841.4 million.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- KeyBanc Downgrades Primoris Services Corporation (PRIM) to Sector Weight
- Morgan Stanley Upgrades CDW Corporation (CDW) to Overweight
- salesforce.com (CRM) Reiterated at Market Outperform by Citizens: Acquiring Fin
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
